{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:49:53Z","timestamp":1774658993396,"version":"3.50.1"},"reference-count":44,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2018,12,2]]},"DOI":"10.1080\/14712598.2018.1544614","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:06:51Z","timestamp":1541376411000},"page":"1199-1207","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?"],"prefix":"10.1080","volume":"18","author":[{"given":"Luke D.","family":"Rothermel","sequence":"first","affiliation":[{"name":",","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.43"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"e_1_3_4_7_1","unstructured":"Amgen. Imlygic (talimogene laherparepvec) suspension for intralesional injection: US presecribing information; 2015 [cited 2018 Aug 2]. Available from: http:\/\/www.fda.gov"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1455825"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.026"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2025-8"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301885"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1274729"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481602300104"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-11"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0759"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.10.66"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.3675"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5286-0"},{"key":"e_1_3_4_20_1","article-title":"Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: a single institution experience","author":"Perez M","unstructured":"Perez M, Miura J, Holstein A, et al. Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: a single institution experience. Ann Surg Oncol. Forthcoming.","journal-title":"Ann Surg Oncol"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7379"},{"issue":"1109","key":"e_1_3_4_22_1","first-page":"e1110","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas A","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(1109\u20131119):e1110.","journal-title":"Cell"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.9568"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.9508"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.132"},{"key":"e_1_3_4_26_1","unstructured":"Viralytics. About CAVATAK(R); 2018 [cited 2018 Aug 21]. Available from: https:\/\/www.viralytics.com\/our-pipeline\/cavatak\/cavataktm\/"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.9030"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-3-S2-P343"},{"issue":"6","key":"e_1_3_4_29_1","first-page":"1051PD","article-title":"The MITCI (phase1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma","volume":"27","author":"Curti B","year":"2016","unstructured":"Curti B, Richards J, Faries MB, et al. The MITCI (phase1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma. Annals of Oncology. 2016;27(supplement_6):1051PD.","journal-title":"Annals of Oncology"},{"key":"e_1_3_4_30_1","doi-asserted-by":"crossref","unstructured":"Curti B Richards J Hallmeyer S et al. Abstract CT114: the MITCI (Phase 1b) study: a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treament. Paper presented at: Proceedings: AACR Annual Meeting 2017; 2017 Apr 1\u20135; Washington (DC).","DOI":"10.1158\/1538-7445.AM2017-CT114"},{"key":"e_1_3_4_31_1","doi-asserted-by":"crossref","unstructured":"Silk AW Kaufman HL Gabrail N et al. Abstract CT026: phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: interim results of the CAPRA clinical trial. Paper presented at: AACR Annual Meeting 2017; 2017 Apr 1\u20135; Washington (DC).","DOI":"10.1158\/1538-7445.AM2017-CT026"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00149"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920112800958814"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.6082"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.9510"},{"key":"e_1_3_4_36_1","unstructured":"SillaJen. Pexa-Vec (JX-594); 2016 [cited 2018 Aug 21]. Available from: http:\/\/www.sillajen.com\/eng\/sub\/eng_sub.aspx?s_code=0201000000"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.3092"},{"key":"e_1_3_4_38_1","unstructured":"Oncolys. Telomelysin(R) (OBP-301); 2018 [cited 2018 Aug 21]. Available from: https:\/\/www.oncolys.com\/en\/pipeline\/telomelysin.html"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0556"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.262"},{"key":"e_1_3_4_41_1","unstructured":"Oncolytics. What is REOLYSIN(R). Calgary AB: Oncolytics Biotech Inc; 2018."},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0524"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.146"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2181"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3260-6"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00555"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2018.1544614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T23:48:10Z","timestamp":1770940090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2018.1544614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,2]]}},"alternative-id":["10.1080\/14712598.2018.1544614"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2018.1544614","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}